Abstract | PURPOSE: METHODS: RESULTS: The best-corrected visual acuity changes at each visit compared with baseline were significantly better in Group 1 (P = 0.01, 0.02, 0.02, 0.009, 0.009, respectively at third, sixth, ninth, 12th month, and last visit). When best-corrected visual acuity was classified according to the change in visual acuity of 10 letters or more, the rate of improved or stable best-corrected visual acuity was greater in Group 1 (P = 0.02). During the follow-up, 5 eyes (14.3%) developed posterior vitreous detachment. CONCLUSION:
|
Authors | Güner Ö Üney, Nurten Ünlü, Mehmet A Acar, Dicle Hazirolan, Uğur E Altiparmak, Zuleyha Yalniz-Akkaya, Firdevs Örnek |
Journal | Retina (Philadelphia, Pa.)
(Retina)
Vol. 34
Issue 1
Pg. 32-7
(Jan 2014)
ISSN: 1539-2864 [Electronic] United States |
PMID | 23751943
(Publication Type: Journal Article)
|
Chemical References |
- Angiogenesis Inhibitors
- Antibodies, Monoclonal, Humanized
- VEGFA protein, human
- Vascular Endothelial Growth Factor A
- Bevacizumab
- Ranibizumab
|
Topics |
- Aged
- Angiogenesis Inhibitors
(therapeutic use)
- Antibodies, Monoclonal, Humanized
(therapeutic use)
- Bevacizumab
- Female
- Follow-Up Studies
- Humans
- Intravitreal Injections
- Male
- Prognosis
- Ranibizumab
- Retina
(pathology)
- Retrospective Studies
- Tomography, Optical Coherence
- Vascular Endothelial Growth Factor A
(antagonists & inhibitors)
- Visual Acuity
(physiology)
- Vitreous Detachment
(physiopathology)
- Wet Macular Degeneration
(drug therapy, physiopathology)
|